Albumin-granulocyte colony stimulating factor fusion protein- Beijing BioFortune/Tianjin SinoBiotech

Drug Profile

Albumin-granulocyte colony stimulating factor fusion protein- Beijing BioFortune/Tianjin SinoBiotech

Alternative Names: Albumin fusion protein – Tianjin; HSA-GCSF; Human Serum Albumin GCSF; rHSA/GCSF fusion protein - Tianjin SinoBiotech

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Beijing Bio-Fortune; Tianjin SinoBiotech
  • Class Albumins; Granulocyte colony-stimulating factors; Recombinant fusion proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Neutropenia

Most Recent Events

  • 06 Sep 2017 Albumin-granulocyte colony stimulating factor fusion protein is still in phase II trials for Neutropenia in China
  • 14 Aug 2017 Tianjin SinoBiotech initiates enrolment in a phase II trial for Neutropenia (Prevention, Chemotherapy-induced) in China (NCT03251768)
  • 10 Apr 2017 Tianjin SinoBiotech completes phase I trial in Neutropaenia (Prevention) in China (SC) (NCT03246009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top